ALFA Filings
Every announcement, straight from the exchange
Every regulatory approval announcement on NSE and BSE that our alert engine sent, newest first.
Time
353 announcements with these filters
Zim Laboratories received Italian regulatory approval for its Dabigatran Etexilate capsules. This authorization facilitates market entry into Italy and potential expansion across Europe.
Lloyds Engineering Works Limited received NOCs from NSE and BSE for its proposed merger scheme. This regulatory milestone enables the company to file the scheme with NCLT.
Lloyds Engineering Works received 'No Objection Certificates' from NSE and BSE for its proposed merger scheme. This key regulatory clearance advances the amalgamation process.
Healthy Life Agritec Limited received the Consent to Operate license for its Bangalore manufacturing unit. Valid until 2035, the license enables commencement of commercial production.
E2E Rail's subsidiary received RDSO prototype testing approval for its Kavach safety system. This qualification step enables participation in upcoming Indian Railway safety technology tenders.
Lupin received tentative U.S. FDA approval for Revefenacin Inhalation Solution, targeting a USD 260.7 million market. This strengthens Lupin's respiratory portfolio in the United States.
FDC Limited received U.S.FDA ANDA approval for Cefixime Oral Suspension USP in two strengths. This regulatory milestone enables the company to market these products in the US.
Lloyds Enterprises received no-objection letters from BSE and NSE for its Composite Scheme of Arrangement. This regulatory milestone allows the company to approach NCLT for final approval.
Aurobindo Pharma subsidiary CuraTeQ received CDSCO marketing approval for Bevqolva, a bevacizumab biosimilar. The authorisation permits domestic manufacturing and marketing for metastatic colorectal cancer treatment.
OneSource Specialty Pharma received Karnataka government approval for its Unit II expansion project. The facility expansion enhances manufacturing capacities to service global partners and support growth.
Siemens Limited received regulatory approval to transition its financial year to an April-March cycle. The current transitional period will span 18 months ending March 2026.
Caplin Point's subsidiary secured USFDA approval for Foscarnet Sodium Injection. The generic drug addresses a US market with approximately ₹142.5 Crore in annual sales.
Lloyds Enterprises announced that CCI approved the merger of three entities into its material subsidiary. This regulatory clearance is a key milestone for the group's consolidation.
Indoco Remedies received EU GMP certification from the Malta Medicines Authority for its Baddi facility. This approval validates compliance with global quality standards for international markets.
Alembic Pharmaceuticals received USFDA tentative approval for Darolutamide Tablets, targeting a ₹29,972.5 Crore market. This approval strengthens the company's oncology portfolio and international growth prospects.
Lupin received US FDA approval for Famotidine Injection, targeting an $8.7 million market. This ₹82.65 Crore opportunity strengthens its presence in the US gastrointestinal segment.
Lloyds Engineering Works received CCI approval for merging three entities into itself. This regulatory milestone advances the consolidation process for the engineering firm.
ABC India Limited received approval for voluntary delisting from the Calcutta Stock Exchange effective May 13, 2026. This administrative change consolidates its listing on the BSE.
Nitiraj Engineers received Government approval to operate a GATC facility. This project expects ₹0.50 Crore annual savings and enhanced operational efficiency through in-house calibration.
Atmastco's subsidiary received BIS certification for Level 6 bulletproof jackets. This milestone enables the company to commence commercial production for the defence market.
Biocon Pharma received Health Canada approval for Micafungin for Injection, USP. This milestone strengthens the company's integrated biosimilars and generics portfolio in Canada.
PB Fintech's subsidiary received SEBI registration to act as a Stock Broker in the NSE debt segment. The approval enables expanded financial services operations for the group.
RNFI Services' subsidiary received AMFI registration valid for three years starting May 2026. This milestone enables the company to expand its mutual fund distribution capabilities.
Gretex Corporate Services announced that Celestial Chakra Trust received SEBI registration as a Category II AIF. The fund will be managed by Bautex Ventures LLP.
Vantage Knowledge Academy received the Certificate of Registration from the Press Registrar General of India. This formalizes the publication of its E-Newspaper, The Campus and Lifestyle.
Ola Electric received government certification for its 4680 Bharat Cell powered S1 X+ scooter. This validates the technology's safety and performance for mass-market deployment.
Sammaan Capital received RBI's 'no objection' for its NBFC business transfer scheme. This key regulatory milestone advances the company's planned corporate restructuring.
The South Indian Bank Limited received RBI approval for Kotak Mahindra Bank Limited to acquire up to a 9.99% aggregate holding in the bank. The approval is subject to compliance with Banking Regulation Act provisions and RBI directions. This regulatory clearance allows Kotak Mahindra Bank to increase its strategic stake in the private lender.
Nitiraj Engineers Limited received approval from the Ministry of Consumer Affairs to operate as a Government Approved Test Centre. Valid until May 2027, the approval authorizes verification of Class III weighing instruments up to 150kg with a monthly capacity of 2,600 units. This regulatory milestone enables the company to undertake official verification services for its manufactured products.
DCB Bank received RBI approval to reappoint M/s Varma & Varma and appoint M/s Deloitte Haskins & Sells as Joint Statutory Auditors for FY 2026-27. Deloitte replaces M/s B S R & Co. LLP. The appointments are subject to shareholder approval at the upcoming Annual General Meeting.